{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:48:04Z","timestamp":1789044484672,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/ftd.0000000000000277","type":"journal-article","created":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T07:42:14Z","timestamp":1453880534000},"page":"383-387","source":"Crossref","is-referenced-by-count":4,"title":["S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction"],"prefix":"10.1097","volume":"38","author":[{"given":"Andrew T.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne N.","family":"Nafziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D. M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Turpault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0091270003252519","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R2-16-20210129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol Ther"},{"key":"R3-16-20210129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/00912700122010618","article-title":"Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe","volume":"41","author":"Kim","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"R4-16-20210129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0091270004265366","article-title":"Limited sampling strategy of S-warfarin concentrations, but not warfarin S\/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers","volume":"44","author":"Ma","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R5-16-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-199001000-00007","article-title":"Validity of a two-point acetaminophen pharmacokinetic study","volume":"12","author":"Scavone","year":"1990","journal-title":"Ther Drug Monit"},{"key":"R6-16-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s002280050688","article-title":"Limited-sampling strategy models for estimating the area under the plasma concentration-s curve for amlodipine","volume":"55","author":"Suarez-Kurtz","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-16-20210129","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1067\/mcp.2002.128867","article-title":"Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer","volume":"72","author":"Di Paolo","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R8-16-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007691-200104000-00003","article-title":"Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms","volume":"23","author":"David","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R9-16-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00007691-200004000-00005","article-title":"Limited sampling strategy for mycophenolic acid area under the curve","volume":"22","author":"Filler","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R10-16-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.2010.158","article-title":"An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors","volume":"88","author":"Goh","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R11-16-20210129","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0091270006287291","article-title":"Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail","volume":"46","author":"Johnson","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R13-16-20210129","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","article-title":"Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-16-20210129","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","article-title":"Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A","volume":"68","author":"Turpault","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R15-16-20210129","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-16-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/0091270010372105","article-title":"Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients","volume":"51","author":"Ignjatovic","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"R17-16-20210129","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/00912700222011418","article-title":"Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques","volume":"42","author":"Kim","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R18-16-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199559040-00011","article-title":"Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals","volume":"59","author":"Kahan","year":"1995","journal-title":"Transplantation"},{"key":"R19-16-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/00912709922007723","article-title":"A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients","volume":"39","author":"Meier-Kriesche","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"R20-16-20210129","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1046\/j.1523-1755.1998.00194.x","article-title":"Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Technical note","volume":"54","author":"Gaspari","year":"1998","journal-title":"Kidney Int"},{"key":"R21-16-20210129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2010.03802.x","article-title":"Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?","volume":"71","author":"Mahmood","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R22-16-20210129","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2005.08.004","article-title":"Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam","volume":"78","author":"Chaobal","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R23-16-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","article-title":"In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration","volume":"11","author":"Lin","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R24-16-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008571-199810000-00001","article-title":"Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes","volume":"8","author":"Takahashi","year":"1998","journal-title":"Pharmacogenetics"},{"key":"R25-16-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mcp.2003.26a","article-title":"Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients","volume":"73","author":"Takahashi","year":"2003","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T13:58:41Z","timestamp":1654178321000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201606000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000277","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}